Overview

Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Guadalajara
Treatments:
Insulin
Insulin, Globin Zinc
Magnesium Oxide